MedTrace Logo

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

NCT06475326 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2024-08-09

No results posted yet for this study

Summary

In this study, Adebrelimab combined with NALIRIFOX conversion therapy was performed in subjects with locally advanced pancreatic cancer to evaluate the efficacy and safety of conversion therapy with immunotherapy combined with chemotherapy, followed by different treatment methods such as surgery, continued conversion therapy, and advanced systemic therapy according to different transformation outcomes, to improve the survival benefit of subjects with locally advanced pancreatic cancer.

Conditions

Interventions

DRUG

Adebrelimab

Adebrelimab ,20mg/Kg per time, Q4W

DRUG

Oxaliplatin 100 MG

Oxaliplatin: 60mg/m2, Q2W

DRUG

Irinotecan liposome

Irinotecan Liposome: 50mg/m2, Q2W

DRUG

Calcium Folinate

Calcium Folinate: 400mg/m2, Q2W

DRUG

Fluorouracil

Fluorouracil: 2400mg/m2, Q2W

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Weijing Zhang · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-05
Primary Completion
2025-06-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06475326 on ClinicalTrials.gov